Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Lirilumab With Nivolumab ± Ipilimumab in Advanced Solid Tumors
jRCT2080223608Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of lirilumab, nivolumab and ipilimumab in Nonhematologic neoplasms (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of lirilumab in combination with nivolumab ± ipilimumab and Pharmacokinetics of lirilumab in combination regimens. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223608.